Daily BriefsUnited States

Daily Brief United States: Workday Inc Class A, Expedia Group, Inc., IonQ , Trade Desk /, Martin Marietta Materials, SharkNinja , Gilead Sciences, Viatris, Royalty Pharma , Akamai Technologies and more

In today’s briefing:

  • Quiddity Leaderboard S&P500 Sep 24 Rebal: Palantir, Apollo, Workday Racing for Mega$ Flows
  • Expedia Group Inc.: A Bear’s Perspective! – Major Drivers
  • IonQ Inc.: Acceleration of Quantum Computing Milestones Driving Our Optimism! – Major Drivers
  • The Trade Desk Inc.: A Story Of Expanded Connected TV (CTV) Partnerships & Retail Media Network Expansion! – Major Drivers
  • Martin Marietta Materials: Leveraging Long-Term Contracts and Increased DOT Spending! – Major Drivers
  • SharkNinja Inc.: These Are The 5 Pivotal Factors Impacting Its Performance In 2025 & Beyond! – Financial Forecasts
  • Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! – Major Drivers
  • Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! – Major Drivers
  • Royalty Pharma: Expanding Clinical and Regulatory Event Horizons! – Major Drivers
  • Akamai Technologies: Will The Acquisition of API Security Leader Noname Security Be A Game Changer? – Major Drivers


Quiddity Leaderboard S&P500 Sep 24 Rebal: Palantir, Apollo, Workday Racing for Mega$ Flows

By Travis Lundy

  • The S&P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
  • In this insight, we take a look at the upcoming constituent changes in the run up to the September 2024 index rebal event.
  • We expect two regular changes in September 2024. There are also several live M&A events which could trigger intra-review index changes in the late-2024/early-2025.

Expedia Group Inc.: A Bear’s Perspective! – Major Drivers

By Baptista Research

  • Expedia Group, in its second-quarter 2024 earnings, exhibited a dual-faced performance characterized by significant achievements and emerging challenges that mirror the broader complexities of the travel industry.
  • The management has focused on revitalizing core brands, particular emphasis on enhancing execution within the company’s consumer segment, and fine-tuning their long-term strategic direction.
  • Under her leadership, Expedia Group has seen a robust growth in room nights and gross bookings indicating a strong recovery trajectory from previous downturns.

IonQ Inc.: Acceleration of Quantum Computing Milestones Driving Our Optimism! – Major Drivers

By Baptista Research

  • IonQ’s second quarter financial and operational performance for 2024 reveals a mix of significant technological advancements and robust commercial progress, underscoring both opportunities and challenges as the company advances in the quantum computing sector.
  • Starting with the financial metrics, IonQ reported a revenue of $11.4 million, surpassing the upper range of its guidance.
  • This indicates effective contract execution and perhaps a growing demand for their quantum computing solutions.

The Trade Desk Inc.: A Story Of Expanded Connected TV (CTV) Partnerships & Retail Media Network Expansion! – Major Drivers

By Baptista Research

  • The Trade Desk reported a robust performance for the second quarter of 2024, with notable year-over-year revenue growth of 26%, totaling $585 million.
  • This growth considerably surpasses the growth rates experienced by peer companies within the digital marketing sector, emphasizing The Trade Desk’s consistent ability to capture increased market share.
  • This trend is particularly highlighted in areas like Connected TV (CTV), which continues to be a strong driver of the company’s expansion.

Martin Marietta Materials: Leveraging Long-Term Contracts and Increased DOT Spending! – Major Drivers

By Baptista Research

  • Martin Marietta’s second quarter 2024 earnings highlighted several key developments and challenges that reflect both positive and negative aspects impacting its performance and future outlook.
  • The company experienced a decrease in product shipments primarily due to an unprecedented increase in rainfall, specifically in the Dallas Fort Worth area, which is a critical market for Martin Marietta.
  • Furthermore, the lagging effects of restrictive monetary policy also pressured demand for private construction, exacerbating the decrease in shipments.

SharkNinja Inc.: These Are The 5 Pivotal Factors Impacting Its Performance In 2025 & Beyond! – Financial Forecasts

By Baptista Research

  • SharkNinja reported its second quarter 2024 earnings with a remarkably robust performance, significantly accelerating its financial growth and expanding its market presence.
  • The company achieved a 38% increase in adjusted net sales and a substantial 48% rise in adjusted EBITDA, indicating strong organic growth.
  • Adjusted earnings per share also soared by 51%, reflecting a successful operational strategy focused on innovation and market expansion.

Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! – Major Drivers

By Baptista Research

  • Gilead Sciences Inc. showcased a solid performance for the second quarter of 2024, marked by robust commercial execution and growth across key therapeutic areas such as HIV, liver diseases, and oncology.
  • Notably, Biktarvy, an HIV treatment, observed an 8% year-over-year growth, while Trodelvy in oncology saw a 23% increase, and cell therapy revenues increased by 11%.
  • Additionally, the company reported disciplined management of operating expenses which significantly contributed to bottom-line growth.

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! – Major Drivers

By Baptista Research

  • Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.
  • Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.
  • This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.

Royalty Pharma: Expanding Clinical and Regulatory Event Horizons! – Major Drivers

By Baptista Research

  • Royalty Pharma experienced a strong second quarter for the 2024 fiscal year, outperforming earlier guidance with a 12% increase in portfolio receipts which include royalty and other income.
  • The company’s robust performance can be attributed to an 11% growth in royalty receipts, indicating solid recurring cash flow from their extensive and high-quality portfolio of more than 35 commercial products.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Akamai Technologies: Will The Acquisition of API Security Leader Noname Security Be A Game Changer? – Major Drivers

By Baptista Research

  • Akamai Technologies’ second quarter of 2024 earnings presentation highlighted a mix of sustained growth and evolving strategic focus amidst industry challenges.
  • The company reported a 5% increase in total revenue year over-year, amounting to $980 million, reflecting steady growth particularly in its security and compute sectors, despite ongoing macroeconomic and geopolitical challenges.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars